OBJECTIVE: The management of liver receivers requires intense immunosuppression to prevent graft rejection. @entity618 ( @entity2098 ) is a common immunosuppressant but frequently suffer dose reduction for gastrointestinal adverse reactions (GI). Hence, the enteric-coated @entity618 (EC-MPS) is introduced as a substitute for @entity2098 to reduce GI. The study was designed to investigate the efficacy, safety and exposure equation of EC-MPS in liver transplant @entity1 in China. METHODS: Ninety-two liver receivers who administered EC-MPS or @entity2098 as a primary immunosuppressant were enrolled in this single-center study and divided into @entity2098 group and EC-MPC group, respectively. Efficacy and safety of EC-MPS were compared with @entity2098 . The @entity3443 exposure was measured at time 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12   h after mean 4.5 days of EC-MPS treatment. An equation of limited time points for estimating serum @entity3443 exposure of EC-MPS was established using multiple stepwise regression model. RESULTS: Data show an interpatient variation in @entity3443 AUC, Cmax and Tmax. After a first dose of EC-MPS, the mean value of serum AUC0-12   h was 20.68 mg/L (SD 8.94, range 8.1-46.3). Cmax was 9.7 mg/L (SD 6.48, range 2.7-16.3); Tmax was 1.90   h (SD 0.97, range 0.5-4). The best equation for estimating the AUC was 6.0 1 4   +   0.946C2   +   0.606C3   +   1.154C4   +   2.479C6   +   5.07C12. Comparing with @entity2098 , EC-MPS not only effectively maintained immunosuppression, but also had similar incidences of @entity8 and @entity1503 . However, EC-MPS markedly improved GI, the incidence of GI was half of the @entity2098 group. CONCLUSION: This analysis presented that EC-MPS is an effective and safe immunosuppressant as similar as @entity2098 . The conversion of @entity2098 to EC-MPS could be administered.

The evaluation of enteric-coated XXXX in cardiac deceased donor liver transplant @entity1 in China.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['infection, renal dysfunction'] @entity3443 :: ('D015097', 'Chemical') :: ['MPA'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological disorders'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate sodium', 'Mycophenolate mofetil']
@entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate sodium']
